Related Experiment Video
Updated: Jun 23, 2026
Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
Published on: June 4, 2012
Evaluation of LPRDA Pentapeptide for the Prevention and Treatment of Staphylococcus aureus Peritoneal Infection
Svetlana A Bozhkova1, Ekaterina M Gordina1, Dmitry V Labutin1
1Vreden National Medical Research Center of Traumatology and Orthopedics, 195427 St. Petersburg, Russia.
Insights
A novel sortase A inhibitor, LPRDA, effectively reduced Staphylococcus aureus bacterial load and inhibited virulence factors like alpha-hemolysin. This antivirulent strategy shows promise for treating infections, especially when combined with antibiotics.
Area of Science:
- Microbiology and Infectious Diseases
- Antimicrobial Resistance
- Drug Discovery
Background:
- Antibiotic resistance in *Staphylococcus aureus* (*S. aureus*) necessitates novel therapeutic strategies targeting virulence factors.
- *S. aureus*-induced peritonitis is a significant concern in dialysis, implant, and trauma patients.
Purpose of the Study:
- To investigate the efficacy of the oligopeptide sortase A inhibitor LPRDA as a non-conventional antibacterial agent for *S. aureus* peritoneal infections.
- To evaluate LPRDA's impact on bacterial load, colonization, and virulence factor production.
Main Methods:
- Administration of LPRDA prior to *S. aureus* challenge in an animal model.
- Assessment of bacterial load in internal organs and abdominal cavity colonization.
- Evaluation of LPRDA's effect on alpha-hemolysin production across various *S. aureus* strains.
Main Results:
- LPRDA administration significantly reduced internal organ bacterial load and abdominal cavity colonization.
- LPRDA inhibited alpha-hemolysin production in 80% of tested *S. aureus* strains.
- LPRDA demonstrated potential for combined use with antibiotics like cefazolin and vancomycin.
Conclusions:
- The sortase A inhibitor LPRDA acts as a promising antivirulent agent against *S. aureus* infections.
- LPRDA offers a non-conventional approach to combatting *S. aureus* peritonitis without impacting bacterial survival.
- Combined therapy with LPRDA and conventional antibiotics may enhance treatment efficacy for *S. aureus* infections.
Abstract:
Targeting virulence determinants is a promising approach to controlling S. aureus infections in the face of the global spread of antibiotic resistance. S. aureus-induced peritonitis often occurs in dialysis, implant and trauma patients. To develop novel prevention and treatment options for peritoneal infection, we investigated the oligopeptide sortase A inhibitor LPRDA as a non-conventional antibacterial that does not affect staphylococcal survival. Administration of LPRDA prior to S. aureus challenge reduced the bacterial load of internal organs and bacterial colonization of the abdominal cavity in animals. In addition, LPRDA inhibited α-hemolysin production in 80% of the 35 reference and clinical S. aureus strains tested. Consequent research of LPRDA interactions with cefazolin and vancomycin has demonstrated the potential for combined application of the antivirulent and antibiotic agents under study.
More Related Videos
06:36PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
Published on: April 9, 2013
06:36Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:25Clinical Significance of Antibiotic Resistance